GlassScriptPhysician profile
Kyle A Rezac
NPI 1124448071
$1,586.03
in general payments reported to CMS, 2019-2025
24 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $139 · 2022: $22.66 · 2023: $42.84 · 2024: $310 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $279.36 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $230.05 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $201.01 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $175.43 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $125.65 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $80.33 | 2019-2024 | |
| Abbvie INC. | $66.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $45.06 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.58 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $39.48 | 2019-2020 | |
| Amarin Pharma, INC. | $37.68 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $33.10 | 2019 | |
| Amgen INC. | $31.72 | 2019-2025 | Otezla, Repatha |
| Exact Sciences Corporation | $29.96 | 2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $22.66 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $21.25 | 2025 | Heplisav-B |
| Dexcom, INC. | $20.37 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.36 | 2025 | Gemtesa |
| Astellas Pharma US INC | $16.75 | 2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $16.68 | 2019 | |
| Concordia Pharmaceuticals INC. | $14.79 | 2019 | |
| Ibsa Pharma INC. | $13.80 | 2020 | |
| Adlon Therapeutics L.P. | $13.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Rezac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.